Overview

Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

Status:
Active, not recruiting
Trial end date:
2025-01-01
Target enrollment:
0
Participant gender:
Male
Summary
This is a trial of 5 fraction SBRT combined with androgen deprivation therapy for patients with localized high-risk or unfavorable intermediate risk prostate cancer
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
VA Greater Los Angeles Healthcare System
Treatments:
Androgens
Criteria
Inclusion Criteria:

- Histologically confirmed primary non-metastatic adenocarcinoma of the prostate

- High-risk or unfavorable intermediate-risk as defined below:

High-risk localized prostate cancer, as defined by any one of the following factors:

Pre-biopsy or any PSA ≥20 prior to enrollment, or Gleason score 8 or higher on any biopsy
core, or cT3a or higher.

Unfavorable intermediate risk localized prostate cancer, as defined as any of the following
factors:

Gleason score of 4+3 or higher on any biopsy core, or Gleason score 3+4 and >50% biopsy
cores positive, or The presence of any two of the following: PSA>10, cT2b-c, Gleason score
3+4 in any core

- No pelvic nodal metastases (based on CT or MRI findings)

- No distant metastases, based upon:

CT scan or MRI of the pelvis within 120 days prior to registration, Bone scan within 120
days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must
be obtained to rule out metastasis

- Age ≥ 18

- KPS ≥ 70 (or ECOG 0-2)

- Ability to understand, and willingness to sign, the written informed consent

Exclusion Criteria:

- Patients with low-risk or favorable intermediate-risk prostate cancer do not meet
inclusion criteria (these patients would be eligible for SBRT off-trial as a standard
of care option)

- Patients with any evidence of distant metastases

- Hormonal therapy (LHRH agonist or oral anti-androgen) exceeding 7 months prior to
registration

- Prior cryosurgery, HIFU or brachytherapy of the prostate

- Prior pelvic radiotherapy

- History of Crohn's Disease or Ulcerative Colitis